Jane Street Group, LLC Relmada Therapeutics, Inc. Transaction History

Jane Street Group, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.93 - $4.94 $403,616 - $680,499	-137,753 Reduced 78.61%	37,476 $112,000
Q1 2024 May 15, 2024	BUY	$3.1 - $6.8 $505,591 - $1.11 Million	163,094 Added 1344.0%	175,229 $814,000
Q4 2023 Feb 14, 2024	BUY	$2.45 - $4.22 $29,730 - $51,209	12,135 New	12,135 $50,000
Q2 2023 Aug 14, 2023	BUY	$2.22 - $3.54 $26,901 - $42,897	12,118 New	12,118 $29,000
Q4 2022 Feb 14, 2023	BUY	$2.17 - $35.84 $257,325 - $4.25 Million	118,583 New	118,583 $413,000
Q2 2022 Aug 16, 2022	SELL	$16.5 - $30.34 $716,017 - $1.32 Million	-43,395 Reduced 77.85%	12,348 $234,000
Q1 2022 May 17, 2022	BUY	$16.72 - $26.99 $932,022 - $1.5 Million	55,743 New	55,743 $1.51 Million
Q3 2021 Nov 16, 2021	SELL	$21.86 - $34.77 $413,569 - $657,813	-18,919 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$29.55 - $39.15 $559,056 - $740,678	18,919 New	18,919 $606,000
Q3 2020 Nov 17, 2020	SELL	$34.42 - $43.78 $643,585 - $818,598	-18,698 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$31.59 - $49.98 $339,971 - $537,884	10,762 Added 135.61%	18,698 $836,000
Q1 2020 May 15, 2020	BUY	$23.78 - $50.12 $188,718 - $397,752	7,936 New	7,936 $271,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $83M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.